Tumor markers are biological substances found in blood, tissues, or other bodily fluids that can indicate the presence of cancer. In modern oncology, these biomarkers serve multiple functions ranging from screening and diagnosis to monitoring treatment efficacy and disease recurrence. However, the interpretation of these values is rarely straightforward. Clinicians must navigate various biochemical nuances and biological variations when evaluating patient test results to ensure appropriate medical management.
One of the most established examples of a targeted biomarker is prostate-specific antigen (PSA), which is widely utilized in the management of prostate disease [4]. Over the years, understanding of PSA biochemistry has evolved significantly. Research has demonstrated that PSA exists in serum in multiple molecular configurations, complexes, and distinct isoforms [4]. Standardization efforts, such as calibration linked to international standards, have improved the consistency of commercial assay kits, helping clinicians compare results more reliably across different testing platforms [4].
Despite such advancements, tumor markers often present unique clinical challenges, particularly in rare or mixed tumor presentations. For instance, specific biomarkers like calcitonin are traditionally used to monitor conditions such as medullary thyroid carcinoma [1]. Yet, in rare occurrences where multiple distinct malignancies coexist within the same tissue—such as a collision tumor involving both medullary and papillary thyroid carcinoma—the expected biomarker relationships can be altered [1]. Following surgical interventions and targeted therapies, tracking markers like calcitonin, carcinoembryonic antigen, and thyroglobulin helps physicians evaluate treatment response, though complex pathology requires exhaustive immunohistochemical confirmation [1].
The field of oncology is also rapidly expanding into advanced molecular approaches, including liquid biopsies and transcriptomic profiling. Modern investigations explore circulating tumor cells, extracellular vesicle RNAs, and circulating non-coding RNAs to better understand tumor heterogeneity and monitor disease progression in endocrine malignancies [8]. While these emerging tools offer a more detailed picture of the transcriptional landscape, translating novel biomarkers from experimental settings into routine clinical practice involves overcoming significant technical and validation hurdles.
Limitations and Challenges in Interpretation
While tumor markers are invaluable clinical assets, they are subject to several inherent limitations:
- Lack of Absolute Specificity: Elevated marker levels do not automatically confirm malignancy, as benign conditions or inflammation can also influence test results.
- Complex Molecular Forms: Biomarkers often circulate in multiple configurations or isoforms, which can affect how standard laboratory assays measure them [4].
- Tumor Heterogeneity: Mixed or rare tumor types can complicate traditional biomarker correlations, requiring secondary diagnostic methods like tissue biopsies and immunohistochemistry [1].
- Translation Barriers: Many advanced circulating biomarkers and liquid biopsy signatures remain under clinical investigation, highlighting a gap between discovery and standardized bedside application [8].
Ultimately, tumor markers should be viewed as one component of a comprehensive diagnostic evaluation rather than standalone definitive answers. Integrating biomarker data with imaging, histopathological analysis, and patient history remains essential for accurate oncological care.
Sources
2. Chemotherapy and cerebral metastases: misperception or reality?
3. Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy
4. Prostate specific antigen: biology, biochemistry and available commercial assays